Search results for: psoriasis

Risankizumab & Apremilast Come to Market in Canada

Michele B. Kaufman, PharmD, BCGP | March 9, 2020

In Canada, five provinces will now reimburse patients with plaque psoriasis who use risankizumab. Also, Canada Health has approved apremilast for treating adults with plaque psoriasis and psoriatic arthritis…

Thoughtful Pediatric Care: Pediatric Cases Require Special Considerations & Aggressive Treatment Plans

Thomas R. Collins | March 9, 2020

From Chronic Low Back Pain to Axial Spondyloarthritis

Mike Fillon | February 13, 2020

ATLANTA—Research into possible genetic drivers of the axial spondyloarthritis (axSpA), including the role of the genetic marker HLA-B27, is advancing, John D. Reveille, MD, professor and vice chair of medicine at the University of Texas McGovern Medical School, Houston, told attendees at the 2019 ACR/ARP Annual Meeting. Dr. Reveille delivered the Philip Hench, MD, Memorial…

Biologic Spending & Price Trends

Arthritis & Rheumatology | January 28, 2020

Any given rheumatology patient who needs a biologic disease-modifying anti-rheumatic drug (DMARD) will spend $22,000–44,000 on their medication each year…

Tips for Smoothing the Time-Consuming Prior Authorization Process

Susan Bernstein | January 17, 2020

ATLANTA—Obtaining prior authorization to ensure services or prescription drugs are covered by a patient’s health plan consumes staff time, and delays or denials may cause patients to abandon treatment, according to speakers at the 2019 ACR/ARP Annual Meeting. In a session on Nov. 10, the experts shared tips to smooth the process. Train Staff on…

Myositis-Specific Antibodies Identified

Mithu Maheswaranathan, MD, & Lisa Criscione-Schreiber, MD, MEd | January 16, 2020

The idiopathic inflammatory myopathies (IIM) encompass eight categories: 1) dermatomyositis (DM) in adults, 2) juvenile dermatomyositis, 3) amyopathic DM, 4) cancer-associated DM, 5) polymyositis, 6) immune-mediated necrotizing myopathy, 7) inclusion body myositis, and 8) overlap myositis.1 These categories help classify the myopathies based on clinical and histologic features. The incidence of IIM is estimated at…

Novartis, Merck & Allergan Join Those Raising U.S. Drug Prices for 2020

Natasha Yetman | January 7, 2020

NEW YORK (Reuters)—Novartis AG, Merck & Co Inc. and Allergan Plc. were among companies that raised U.S. prices on more than 100 prescription medicines on Jan. 4, bringing the tally to 445 drugs that will cost more in 2020, according to data analyzed by healthcare research firm 3 Axis Advisors. That is above the average…

Ankylosing Spondylitis & Uveitis: An Ophthalmologist’s Perspective

Jason Liebowitz, MD, FACR | December 18, 2019

It’s often said the eyes are the window to the soul, and in the case of ankylosing spondylitis and other spondyloarthropathies, one can also say the eyes are the window to systemic disease. Although uveitis occurs in approximately 2–5% of patients with inflammatory bowel disease, 6–9% of patients with psoriatic arthritis and 25% of patients…

The 2019 ACR Award Winners & Distinguished Fellows

Carol Patton | December 18, 2019

ATLANTA—Every year at its Annual Meeting, the ACR recognizes its members’ outstanding contributions to the field of rheumatology through an awards program. The ACR is proud to announce 20 award recipients for 2019, honored for their accomplishments as clinicians, instructors or researchers who have helped advance rheumatology, for their commitment to inspire others to enter…

Hair dye being applied to a man’s beard.

Case Report: A 50-Year-Old Man Suffers Dye-Induced Arthritis

Hrudya Abraham, MD, Eric Warm, MD, FACP, & Avis Ware, MD | December 18, 2019

Hair dye products are commonly used by both men and women to enhance youth and beauty and to follow fashion trends. As reported in the medical literature, hair dyes and their ingredients are associated with allergic contact dermatitis. A possible association with joint inflammation has also been recognized. There is literature to support that para-phenylenediamine…